192 related articles for article (PubMed ID: 34445705)
1. Molecular Dynamics-Derived Pharmacophore Model Explaining the Nonselective Aspect of K
Toplak Ž; Merzel F; Pardo LA; Peterlin Mašič L; Tomašič T
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445705
[TBL] [Abstract][Full Text] [Related]
2. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
3. Dronedarone blockage of the tumor-related Kv10.1 channel: a comparison with amiodarone.
Meléndez TA; Huanosta-Gutiérrez A; Barriga-Montoya C; González-Andrade M; Gómez-Lagunas F
Pflugers Arch; 2020 Jan; 472(1):75-87. PubMed ID: 31897736
[TBL] [Abstract][Full Text] [Related]
4. Procyanidin B1, a novel and specific inhibitor of Kv10.1 channel, suppresses the evolution of hepatoma.
Na W; Ma B; Shi S; Chen Y; Zhang H; Zhan Y; An H
Biochem Pharmacol; 2020 Aug; 178():114089. PubMed ID: 32533968
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the K
Barriga-Montoya C; Huanosta-Gutiérrez A; Reyes-Vaca A; Hernández-Cruz A; Picones A; Gómez-Lagunas F
Pflugers Arch; 2018 Mar; 470(3):491-503. PubMed ID: 29218452
[TBL] [Abstract][Full Text] [Related]
6. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
7. 3D Pharmacophore-Based Discovery of Novel K
Toplak Ž; Hendrickx LA; Gubič Š; Možina Š; Žegura B; Štern A; Novak M; Shi X; Peigneur S; Tytgat J; Tomašič T; Pardo LA; Mašič LP
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808994
[TBL] [Abstract][Full Text] [Related]
8. Thallium-sensitive fluorescent assay reveals loperamide as a new inhibitor of the potassium channel Kv10.1.
Loza-Huerta A; Milo E; Picones A; Hernández-Cruz A; Luis E
Pharmacol Rep; 2021 Dec; 73(6):1744-1753. PubMed ID: 34213738
[TBL] [Abstract][Full Text] [Related]
9. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
10. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Sintra Grilo L; Carrupt PA; Abriel H; Daina A
Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711
[TBL] [Abstract][Full Text] [Related]
11. Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
Kratz JM; Schuster D; Edtbauer M; Saxena P; Mair CE; Kirchebner J; Matuszczak B; Baburin I; Hering S; Rollinger JM
J Chem Inf Model; 2014 Oct; 54(10):2887-901. PubMed ID: 25148533
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity.
Koulgi S; Jani V; Nair V; Saini JS; Phukan S; Sonavane U; Joshi R; Kamboj R; Palle V
J Biomol Struct Dyn; 2022 Aug; 40(13):5996-6012. PubMed ID: 33494645
[TBL] [Abstract][Full Text] [Related]
13. Expanding the pharmacological profile of κ-hefutoxin 1 and analogues: A focus on the inhibitory effect on the oncogenic channel K
Moreels L; Peigneur S; Yamaguchi Y; Vriens K; Waelkens E; Zhu S; Thevissen K; Cammue BPA; Sato K; Tytgat J
Peptides; 2017 Dec; 98():43-50. PubMed ID: 27578329
[TBL] [Abstract][Full Text] [Related]
14. Gating Modulation of the Tumor-Related Kv10.1 Channel by Mibefradil.
Gómez-Lagunas F; Carrillo E; Pardo LA; Stühmer W
J Cell Physiol; 2017 Aug; 232(8):2019-2032. PubMed ID: 27255432
[TBL] [Abstract][Full Text] [Related]
15. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
16. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
18. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
Du-Cuny L; Chen L; Zhang S
J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220
[TBL] [Abstract][Full Text] [Related]
19. Development of Safe Drugs: The hERG Challenge.
Kalyaanamoorthy S; Barakat KH
Med Res Rev; 2018 Mar; 38(2):525-555. PubMed ID: 28467598
[TBL] [Abstract][Full Text] [Related]
20. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
